Context: Bariatric surgery has become the most effective method for producing weight loss in obese patients. The evaluation of improvement of comorbidities and changes in the quality of life are important outcome factors; however, it is necessary to investigate whether they persist over the long term.

Methods: A cross-sectional study was conducted on 143 obese patients from our institution from February 2007 to February 2008. These patients were divided into five independent groups, one being a control group, plus four other groups with 1, 2, 3, 4 or more years following surgical Roux-en-Y gastric bypass with a silicon ring banded. quality of life forms and anthropometric measurements were performed and its scores correlated with social factors, weight loss success, and status of obesity-related conditions.

Results: For the group that was 1 year postoperative, a significant percentage of excess body weight loss (EBWL%) of 81.7% was observed. The groups with 2, 3, 4 or more years of post-surgical follow-up showed a EBWL decline, but without significant difference. The main comorbidity percentages in all patients who had the surgery was as follows: 69.7% for hypertension; 88.2% for diabetes mellitus; and 27.5% for arthropathy. There was a significant decrease in the rate for diabetes resolution (P = 0.035) observed by evolutionary assessment of the comorbidity resolution. The results obtained by BAROS were good, very good, or excellent in more than 96% of patients in all evaluations that were performed. The use of the Moorehead-Ardelt Questionnaire (M/A) demonstrated improvement in the quality of life. Moreover, the quality of life, when evaluated through SF-36, also showed improvement in all related areas after 1 year; however, after 4 years, improvement remained elevated only in the areas of general state of health and functional capacity.

Conclusions: The Roux-en-Y gastric bypass procedure was able to achieve EBWL of 81.7% after 1 year following surgery, remaining steady with little decline after this period. Important resolution of comorbidities, such as hypertension and diabetes, was also seen. Immediate surgical outcomes assessed by SF-36 and M/A in the area of quality of life were satisfactory, but the general state of health and functional capacity areas were sustained satisfactory at a later time only.

Download full-text PDF

Source
http://dx.doi.org/10.1590/s0004-28032014000300002DOI Listing

Publication Analysis

Top Keywords

quality life
24
weight loss
16
roux-en-y gastric
12
gastric bypass
12
obese patients
8
groups years
8
general state
8
state health
8
health functional
8
life
6

Similar Publications

Transposable elements shape the landscape of heterozygous structural variation in a bird genome.

Zool Res

January 2025

Integrative Science Center of Germplasm Creation in Western China (Chongqing) Science City, MOE Key Laboratory of Freshwater Fish Reproduction and Development, School of Life Sciences, Southwest University, Chongqing 400715, China. E-mail:

Avian genomes exhibit compact organization and remarkable chromosomal stability. However, the extent and mechanisms by which structural variation in avian genomes differ from those in other vertebrate lineages are poorly explored. This study generated a diploid genome assembly for the golden pheasant ( ), a species distinguished by the vibrant plumage of males.

View Article and Find Full Text PDF

Reductive Adjuvant Nanosystem for Alleviated Atopic Dermatitis Syndromes.

ACS Nano

January 2025

College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou, Zhejiang 310058, P. R. China.

Atopic dermatitis (AD) is a recurrent and chronic inflammatory skin condition characterized by a high lifetime prevalence and significant impairment of patients' quality of life, primarily due to intense itching and discomfort. However, current pharmacological interventions provide only moderate efficacy and are frequently accompanied by adverse side effects. The immune-pathogenesis of AD involves dysregulation of the Th2 immune response and exacerbation of inflammation related to excessive reactive oxygen species (ROS).

View Article and Find Full Text PDF

Minimising inhaled corticosteroids for COPD.

Afr J Prim Health Care Fam Med

December 2024

Department of Anaesthesiology, Pharmacology and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver.

This Therapeutic Letter considers the evidence for inhaled corticosteroids (ICS) as a treatment for Chronic Obstructive Pulmonary Disease (COPD). Drug therapy aims to alleviate symptoms, enhance functional capacity and prevent exacerbations, but has not consistently shown to reduce mortality or improve quality of life based on randomised trials.Inhaled corticosteroids have shown limited benefits for COPD symptoms and exacerbations but increased risks of serious harms.

View Article and Find Full Text PDF

[ORL : what's new in 2024].

Rev Med Suisse

January 2025

Service d'oto-rhino-laryngologie et de chirurgie cervico-faciale, Centre hospitalier universitaire vaudois, 1011 Lausanne.

This article highlights recent advancements in otorhinolaryngology. It reviews innovations in managing sudden sensory-neural hearing loss through low-dose glucocorticoid treatments and explores pediatric audiology breakthroughs, particularly gene therapy for DFNB9 deafness. In speech pathology and oncology, a new minimally invasive robotic surgical approach enhances organ preservation for head and neck cancers.

View Article and Find Full Text PDF

[Neurorehabilitation in Parkinson's disease : focus on physical therapy].

Rev Med Suisse

January 2025

Service de neurologie, Clinique bernoise Montana, 3963 Crans-Montana.

Parkinson's disease affects around 6 million people worldwide. It causes both motor and non-motor symptoms. Since there is no cure, medical treatment aims to improve patients' quality of life.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!